Gastrointestinal dysfunction contributes to weight loss in Huntington's disease mice

Neurobiology of Disease

Volumn 44, Issue 1, 2011, Pages 1-8

  Van der Burg, Jorien M M ^a   Winqvist, Annika ^a   Aziz, N Ahmad ^b   Maat Schieman, Marion L C ^b   Roos, Raymund A C ^b   Bates, Gillian P ^c   Brundin, Patrik ^a   Björkqvist, Maria ^a   Wierup, Nils ^a  

^a LUND UNIVERSITY   (Sweden)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Diarrhea; Enteric nervous system; Gastrointestinal motility; Gut; Huntington's disease; Malabsorption; R6 2 mouse; Weight loss

Indexed keywords

NEUROPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; GASTROINTESTINAL MOTILITY DISORDER; GASTROINTESTINAL TRACT; HUNTINGTON CHOREA; INTESTINE INNERVATION; INTESTINE MUCOSA; INTESTINE VILLUS; MALABSORPTION; MALE; MOUSE; NEUROPATHOLOGY; NONHUMAN; PATHOLOGICAL ANATOMY; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN LOCALIZATION; TISSUE DISTRIBUTION; WEIGHT REDUCTION;

AGING; ANIMALS; BODY WEIGHT; ENTERIC NERVOUS SYSTEM; FECES; FEMALE; GASTRIC MUCOSA; GASTROINTESTINAL DISEASES; GASTROINTESTINAL MOTILITY; HUNTINGTON DISEASE; IMMUNOHISTOCHEMISTRY; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; MALABSORPTION SYNDROMES; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEURONS; WATER; WEIGHT LOSS;

EID: 79961127043     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2011.05.006     Document Type: Article

References (66)

1. Andrich J.E., Wobben M., Klotz P., Goetze O., Saft C. Upper gastrointestinal findings in Huntington's disease: patients suffer but do not complain. J. Neural Transm. 2009, 116:1607-1611.
2. Aziz N.A., van der Burg J.M., Landwehrmeyer G.B., Brundin P., Stijnen T., Roos R.A. Weight loss in Huntington disease increases with higher CAG repeat number. Neurology 2008, 71:1506-1513.
3. Aziz N.A., Pijl H., Frolich M., Snel M., Streefland T.C., Roelfsema F., Roos R.A. Systemic energy homeostasis in Huntington's disease patients. J. Neurol. Neurosurg. Psychiatry 2010, 81:1233-1237.
4. Aziz N.A., Pijl H., Frolich M., van der Graaf A.W., Roelfsema F., Roos R.A. Leptin secretion rate increases with higher CAG repeat number in Huntington's disease patients. Clin. Endocrinol. (Oxf) 2010, 73:206-211.
5. Banerjee R., Beal M.F., Thomas B. Autophagy in neurodegenerative disorders: pathogenic roles and therapeutic implications. Trends Neurosci. 2010, 33:541-549.
6. Bjorkqvist M., Petersen A., Bacos K., Isaacs J., Norlen P., Gil J., Popovic N., Sundler F., Bates G.P., Tabrizi S.J., Brundin P., Mulder H. Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease. Hum. Mol. Genet. 2006, 15:1713-1721.
7. Bonelli R.M., Bonelli C.M., Obermayer-Pietsch B. Osteoporosis in Huntington's disease due to neuroleptic medication?. Eur. Neuropsychopharmacol. 2002, 12:S367.
8. Bushara K.O., Nance M., Gomez C.M. Antigliadin antibodies in Huntington's disease. Neurology 2004, 62:132-133.
9. Carter R.J., Lione L.A., Humby T., Mangiarini L., Mahal A., Bates G.P., Dunnett S.B., Morton A.J. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J. Neurosci. 1999, 19:3248-3257.
10. Chiang M.C., Chen H.M., Lee Y.H., Chang H.H., Wu Y.C., Soong B.W., Chen C.M., Wu Y.R., Liu C.S., Niu D.M., Wu J.Y., Chen Y.T., Chern Y. Dysregulation of C/EBPalpha by mutant Huntingtin causes the urea cycle deficiency in Huntington's disease. Hum. Mol. Genet. 2007, 16:483-498.
11. Chiang M.C., Chen C.M., Lee M.R., Chen H.W., Chen H.M., Wu Y.S., Hung C.H., Kang J.J., Chang C.P., Chang C., Wu Y.R., Tsai Y.S., Chern Y. Modulation of energy deficiency in Huntington's disease via activation of the peroxisome proliferator-activated receptor gamma. Hum. Mol. Genet. 2010, 19:4043-4058.
12. Davies K.N., King D., Billington D., Barrett J.A. Intestinal permeability and orocaecal transit time in elderly patients with Parkinson's disease. Postgrad. Med. J. 1996, 72:164-167.
13. Djousse L., Knowlton B., Cupples L.A., Marder K., Shoulson I., Myers R.H. Weight loss in early stage of Huntington's disease. Neurology 2002, 59:1325-1330.
14. Fain J.N., Del Mar N.A., Meade C.A., Reiner A., Goldowitz D. Abnormalities in the functioning of adipocytes from R6/2 mice that are transgenic for the Huntington's disease mutation. Hum. Mol. Genet. 2001, 10:145-152.
15. Farrer L.A., Yu P.L. Anthropometric discrimination among affected, at-risk, and not-at-risk individuals in families with Huntington disease. Am. J. Med. Genet. 1985, 21:307-316.
16. Gabery S., Murphy K., Schultz K., Loy C.T., McCusker E., Kirik D., Halliday G., Petersen A. Changes in key hypothalamic neuropeptide populations in Huntington disease revealed by neuropathological analyses. Acta Neuropathol. 2010, 120:777-788.
17. Goodman A.O., Barker R.A. Body composition in premanifest Huntington's disease reveals lower bone density compared to controls. PLoS Curr. 2011, 3:RRN1214.
18. Goodman A.O., Murgatroyd P.R., Medina-Gomez G., Wood N.I., Finer N., Vidal-Puig A.J., Morton A.J., Barker R.A. The metabolic profile of early Huntington's disease-a combined human and transgenic mouse study. Exp. Neurol. 2008, 210:691-698.
19. Gu M., Gash M.T., Mann V.M., Javoy-Agid F., Cooper J.M., Schapira A.H. Mitochondrial defect in Huntington's disease caudate nucleus. Ann. Neurol. 1996, 39:385-389.
20. HDCRG A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 1993, 72:971-983.
21. Hickey M.A., Gallant K., Gross G.G., Levine M.S., Chesselet M.F. Early behavioral deficits in R6/2 mice suitable for use in preclinical drug testing. Neurobiol. Dis. 2005, 20:1-11.
22. Hockly E., Woodman B., Mahal A., Lewis C.M., Bates G. Standardization and statistical approaches to therapeutic trials in the R6/2 mouse. Brain Res. Bull. 2003, 61:469-479.
23. Hodges A., Strand A.D., Aragaki A.K., Kuhn A., Sengstag T., Hughes G., Elliston L.A., Hartog C., Goldstein D.R., Thu D., Hollingsworth Z.R., Collin F., Synek B., Holmans P.A., Young A.B., Wexler N.S., Delorenzi M., Kooperberg C., Augood S.J., Faull R.L., Olson J.M., Jones L., Luthi-Carter R. Regional and cellular gene expression changes in human Huntington's disease brain. Hum. Mol. Genet. 2006, 15:965-977.
24. Hoogeveen A.T., Willemsen R., Meyer N., de Rooij K.E., Roos R.A., van Ommen G.J., Galjaard H. Characterization and localization of the Huntington disease gene product. Hum. Mol. Genet. 1993, 2:2069-2073.
25. Hult S., Soylu R., Bjorklund T., Belgardt B.F., Mauer J., Bruning J.C., Kirik D., Petersen A. Mutant huntingtin causes metabolic imbalance by disruption of hypothalamic neurocircuits. Cell Metab. 2011, 13:428-439.
26. Kim J., Moody J.P., Edgerly C.K., Bordiuk O.L., Cormier K., Smith K., Beal M.F., Ferrante R.J. Mitochondrial loss, dysfunction and altered dynamics in Huntington's disease. Hum. Mol. Genet. 2010, 19:3919-3935.
27. Lanska D.J., Lanska M.J., Lavine L., Schoenberg B.S. Conditions associated with Huntington's disease at death. A case-control study. Arch. Neurol. 1988, 45:878-880.
28. Lodi R., Schapira A.H., Manners D., Styles P., Wood N.W., Taylor D.J., Warner T.T. Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Ann. Neurol. 2000, 48:72-76.
29. Luthi-Carter R., Hanson S.A., Strand A.D., Bergstrom D.A., Chun W., Peters N.L., Woods A.M., Chan E.Y., Kooperberg C., Krainc D., Young A.B., Tapscott S.J., Olson J.M. Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Hum. Mol. Genet. 2002, 11:1911-1926.
30. Malamut G., Matysiak-Budnik T., Grosdider E., Jais J.P., Morales E., Damotte D., Caillat-Zucman S., Brousse N., Cerf-Bensussan N., Jian R., Cellier C. Adult celiac disease with severe or partial villous atrophy: a comparative study. Gastroenterol. Clin. Biol. 2008, 32:236-242.
31. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., Bates G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87:493-506.
32. Marder K., Zhao H., Eberly S., Tanner C.M., Oakes D., Shoulson I. Dietary intake in adults at risk for Huntington disease: analysis of PHAROS research participants. Neurology 2009, 73:385-392.
33. Mochel F., Charles P., Seguin F., Barritault J., Coussieu C., Perin L., Le B.Y., Gervais C., Carcelain G., Vassault A., Feingold J., Rabier D., Durr A. Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression. PLoS One 2007, 2:e647.
34. Moffitt H., McPhail G.D., Woodman B., Hobbs C., Bates G.P. Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease. PLoS One 2009, 4:e8025.
35. Morales L.M., Estevez J., Suarez H., Villalobos R., Chacin de B.L., Bonilla E. Nutritional evaluation of Huntington disease patients. Am. J. Clin. Nutr. 1989, 50:145-150.
36. Myers R.H., Sax D.S., Koroshetz W.J., Mastromauro C., Cupples L.A., Kiely D.K., Pettengill F.K., Bird E.D. Factors associated with slow progression in Huntington's disease. Arch. Neurol. 1991, 48:800-804.
37. Nagakura Y., Naitoh Y., Kamato T., Yamano M., Miyata K. Compounds possessing 5-HT3 receptor antagonistic activity inhibit intestinal propulsion in mice. Eur. J. Pharmacol. 1996, 311:67-72.
38. Nance M.A., Sanders G. Characteristics of individuals with Huntington disease in long-term care. Mov. Disord. 1996, 11:542-548.
39. Novak M.J., Tabrizi S.J. Huntington's disease. BMJ 2010, 340:c3109.
40. Panov A.V., Gutekunst C.A., Leavitt B.R., Hayden M.R., Burke J.R., Strittmatter W.J., Greenamyre J.T. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat. Neurosci. 2002, 5:731-736.
41. Panov A.V., Burke J.R., Strittmatter W.J., Greenamyre J.T. In vitro effects of polyglutamine tracts on Ca2+-dependent depolarization of rat and human mitochondria: relevance to Huntington's disease. Arch. Biochem. Biophys. 2003, 410:1-6.
42. Panov A.V., Lund S., Greenamyre J.T. Ca2+-induced permeability transition in human lymphoblastoid cell mitochondria from normal and Huntington's disease individuals. Mol. Cell. Biochem. 2005, 269:143-152.
43. Petersen A., Gil J., Maat-Schieman M.L., Bjorkqvist M., Tanila H., Araujo I.M., Smith R., Popovic N., Wierup N., Norlen P., Li J.Y., Roos R.A., Sundler F., Mulder H., Brundin P. Orexin loss in Huntington's disease. Hum. Mol. Genet. 2005, 14:39-47.
44. Pfeiffer R.F. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol. 2003, 2:107-116.
45. Pfeiffer R.F. Neurologic presentations of gastrointestinal disease. Neurol. Clin. 2010, 28:75-87.
46. Phan J., Hickey M.A., Zhang P., Chesselet M.F., Reue K. Adipose tissue dysfunction tracks disease progression in two Huntington's disease mouse models. Hum. Mol. Genet. 2009, 18:1006-1016.
47. Pouladi M.A., Xie Y., Skotte N.H., Ehrnhoefer D.E., Graham R.K., Kim J.E., Bissada N., Yang X.W., Paganetti P., Friedlander R.M., Leavitt B.R., Hayden M.R. Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression. Hum. Mol. Genet. 2010, 19:1528-1538.
48. Pratley R.E., Salbe A.D., Ravussin E., Caviness J.N. Higher sedentary energy expenditure in patients with Huntington's disease. Ann. Neurol. 2000, 47:64-70.
49. Ribchester R.R., Thomson D., Wood N.I., Hinks T., Gillingwater T.H., Wishart T.M., Court F.A., Morton A.J. Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington's disease mutation. Eur. J. Neurosci. 2004, 20:3092-3114.
50. Robbins A.O., Ho A.K., Barker R.A. Weight changes in Huntington's disease. Eur. J. Neurol. 2006, 13:e7.
51. Saleh N., Moutereau S., Durr A., Krystkowiak P., Azulay J.P., Tranchant C., Broussolle E., Morin F., Bachoud-Levi A.C., Maison P. Neuroendocrine disturbances in Huntington's disease. PLoS One 2009, 4:e4962.
52. Sanberg P.R., Fibiger H.C., Mark R.F. Body weight and dietary factors in Huntington's disease patients compared with matched controls. Med. J. Aust. 1981, 1:407-409.
53. Sarkar S., Rubinsztein D.C. Huntington's disease: degradation of mutant huntingtin by autophagy. FEBS J. 2008, 275:4263-4270.
54. Sassone J., Colciago C., Cislaghi G., Silani V., Ciammola A. Huntington's disease: the current state of research with peripheral tissues. Exp. Neurol. 2009, 219:385-397.
55. Sathasivam K., Hobbs C., Turmaine M., Mangiarini L., Mahal A., Bertaux F., Wanker E.E., Doherty P., Davies S.W., Bates G.P. Formation of polyglutamine inclusions in non-CNS tissue. Hum. Mol. Genet. 1999, 8:813-822.
56. Shoulson I., Fahn S. Huntington disease: clinical care and evaluation. Neurology 1979, 29:1-3.
57. Tarmure S., Cristea A., Sampelean D., Negrean V., Alexescu T. Serological and histological correlations in celiac disease. Rom. J. Intern. Med. 2007, 45:263-268.
58. Trejo A., Tarrats R.M., Alonso M.E., Boll M.C., Ochoa A., Velasquez L. Assessment of the nutrition status of patients with Huntington's disease. Nutrition 2004, 20:192-196.
59. Turner C., Schapira A.H. Mitochondrial matters of the brain: the role in Huntington's disease. J. Bioenerg. Biomembr. 2010, 42:193-198.
60. Van der Burg J.M., Bacos K., Wood N.I., Lindqvist A., Wierup N., Woodman B., Wamsteeker J.I., Smith R., Deierborg T., Kuhar M.J., Bates G.P., Mulder H., Erlanson-Albertsson C., Morton A.J., Brundin P., Petersen A., Bjorkqvist M. Increased metabolism in the R6/2 mouse model of Huntington's disease. Neurobiol. Dis. 2008, 29:41-51.
61. Van der Burg J.M., Bjorkqvist M., Brundin P. Beyond the brain: widespread pathology in Huntington's disease. Lancet Neurol. 2009, 8:765-774.
62. Van Raamsdonk J.M., Murphy Z., Selva D.M., Hamidizadeh R., Pearson J., Petersen A., Bjorkqvist M., Muir C., Mackenzie I.R., Hammond G.L., Vogl A.W., Hayden M.R., Leavitt B.R. Testicular degeneration in Huntington disease. Neurobiol. Dis. 2007, 26:512-520.
63. Vonsattel J.P., DiFiglia M. Huntington disease. J. Neuropathol. Exp. Neurol. 1998, 57:369-384.
64. Wang K.S., Ma T., Filiz F., Verkman A.S., Bastidas J.A. Colon water transport in transgenic mice lacking aquaporin-4 water channels. Am. J. Physiol. Gastrointest. Liver Physiol. 2000, 279:G463-G470.
65. Wang H., Lim P.J., Karbowski M., Monteiro M.J. Effects of overexpression of huntingtin proteins on mitochondrial integrity. Hum. Mol. Genet. 2009, 18:737-752.
66. Wood N.I., Goodman A.O., van der Burg J.M., Gazeau V., Brundin P., Bjorkqvist M., Petersen A., Tabrizi S.J., Barker R.A., Morton A.J. Increased thirst and drinking in Huntington's disease and the R6/2 mouse. Brain Res. Bull. 2008, 76:70-79.